{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T20:26:57Z","timestamp":1783110417711,"version":"3.54.6"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bmc.2026.118707","type":"journal-article","created":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T22:57:06Z","timestamp":1779058626000},"page":"118707","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Discovery of potential covalent TYK2 inhibitors targeting Cys736 for the treatment of psoriasis"],"prefix":"10.1016","volume":"139","author":[{"given":"Han","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengwei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingjian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2026.118707_bb0005","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1016\/S0140-6736(23)00457-9","article-title":"Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK","volume":"401","author":"Conrad","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.bmc.2026.118707_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.122991","article-title":"Advances in psoriasis research: from pathogenesis to therapeutics","volume":"355","author":"Sugumaran","year":"2024","journal-title":"Life Sci"},{"key":"10.1016\/j.bmc.2026.118707_bb0015","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.bmc.2026.118707_bb0020","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/ni.3691","article-title":"Mechanisms and consequences of jak\u2013STAT signaling in the immune system","volume":"18","author":"Villarino","year":"2017","journal-title":"Nat Immunol"},{"key":"10.1016\/j.bmc.2026.118707_bb0025","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.3390\/ijms22094983","article-title":"Psoriasis: from pathogenesis to pharmacological and Nano-technological-based therapeutics","volume":"22","author":"Petit","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2026.118707_bb0030","doi-asserted-by":"crossref","first-page":"20059","DOI":"10.1074\/jbc.R700016200","article-title":"JAK-STAT Signaling: from interferons to cytokines","volume":"282","author":"Schindler","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2026.118707_bb0035","doi-asserted-by":"crossref","first-page":"27261","DOI":"10.1074\/jbc.M115.672048","article-title":"Structural and functional characterization of the JH2 Pseudokinase domain of JAK family tyrosine kinase 2 (TYK2)","volume":"290","author":"Min","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2026.118707_bb0040","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jaad.2021.07.002","article-title":"Janus kinase inhibitors in dermatology: part I. A comprehensive review","volume":"86","author":"Chapman","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.bmc.2026.118707_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2023.129235","article-title":"Design, synthesis and biological evaluation of novel N-(methyl-d(3)) pyridazine-3-carboxamide derivatives as TYK2 inhibitors","volume":"86","author":"Liu","year":"2023","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2026.118707_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.pscia.2024.100052","article-title":"Novel targeted therapies in chronic myeloid leukemia","volume":"2","author":"Ashaq","year":"2024","journal-title":"Pharm Sci Adv"},{"key":"10.1016\/j.bmc.2026.118707_bb0055","doi-asserted-by":"crossref","first-page":"7560","DOI":"10.1021\/acs.jmedchem.5c00027","article-title":"Discovery of a highly potent and selective tyrosine kinase 2 (TYK2) degrader with in vivo therapeutic efficacy in a murine psoriasis model","volume":"68","author":"Xiong","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118707_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117114","article-title":"Tyrosine kinase 2 inhibitors: synthesis and applications in the treatment of autoimmune diseases","volume":"283","author":"Pan","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118707_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107430","article-title":"Discovery of selective TYK2 inhibitors: design, synthesis, in vitro and in silico studies of promising hits with triazolopyrimidinone scaffold","volume":"148","author":"Istanbullu","year":"2024","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2026.118707_bb0070","doi-asserted-by":"crossref","first-page":"13561","DOI":"10.1021\/acs.jmedchem.0c00948","article-title":"Discovery of tyrosine kinase 2 (TYK2) inhibitor (PF-06826647) for the treatment of autoimmune diseases","volume":"63","author":"Gerstenberger","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118707_bb0075","doi-asserted-by":"crossref","first-page":"8545","DOI":"10.1021\/acs.jmedchem.4c00769","article-title":"Discovery of GLPG3667, a selective ATP competitive tyrosine kinase 2 inhibitor for the treatment of autoimmune diseases","volume":"67","author":"Mammoliti","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118707_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106642","article-title":"Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis","volume":"189","author":"Roskoski","year":"2023","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.bmc.2026.118707_bb0085","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1021\/acs.jmedchem.0c01698","article-title":"Discovery of BMS-986202: a clinical Tyk2 inhibitor that binds to Tyk2 JH2","volume":"64","author":"Liu","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118707_bb0090","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.2174\/0929867330666230324163414","article-title":"Targeting TYK2 for fighting diseases: recent advance of TYK2 inhibitors","volume":"31","author":"Du","year":"2024","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.bmc.2026.118707_bb0095","doi-asserted-by":"crossref","first-page":"8597","DOI":"10.1021\/acs.jmedchem.8b00917","article-title":"Dual inhibition of TYK2 and JAK1 for the treatment of autoimmune diseases: discovery of ((S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)","volume":"61","author":"Fensome","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118707_bb0100","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1021\/acs.jmedchem.0c01468","article-title":"Discovery of 3-(4-(2-((1H-Indol-5-yl)amino)-5-fluoropyrimidin-4-yl)-1H-pyrazol-1-yl)propanenitrile derivatives as selective TYK2 inhibitors for the treatment of inflammatory bowel disease","volume":"64","author":"Zhang","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118707_bb0105","doi-asserted-by":"crossref","first-page":"8973","DOI":"10.1021\/acs.jmedchem.9b00444","article-title":"Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165","volume":"62","author":"Wrobleski","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118707_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107059","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2024 update","volume":"200","author":"Roskoski","year":"2024","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.bmc.2026.118707_bb0115","first-page":"1363","article-title":"Covalent inhibitors: back on track, future","volume":"12","author":"Gehringer","year":"2020","journal-title":"Med Chem"},{"key":"10.1016\/j.bmc.2026.118707_bb0120","doi-asserted-by":"crossref","first-page":"10513","DOI":"10.1021\/acs.jmedchem.4c01308","article-title":"Covalent inhibitors: to infinity and beyond","volume":"67","author":"Raouf","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118707_bb0125","doi-asserted-by":"crossref","unstructured":"S. Guo, T.-t. Li, G.-h. Ge, H. Hu, W.-h. Xue, Y.-p. Wang, X. Zhang, H.-y. Liu, J.-w. Liang, Y. Zhang, F.-h. Meng, T.-j. Zhang, Discovery of novel 2-azabicyclo[3.2.1]octane derivatives against non-small cell lung cancer from aconitine simplification, Bioorg Chem, 168 (2026) 109360.","DOI":"10.1016\/j.bioorg.2025.109360"},{"key":"10.1016\/j.bmc.2026.118707_bb0130","doi-asserted-by":"crossref","unstructured":"G.-h. Ge, S. Guo, T.-t. Li, Y.-p. Wang, L.-r. Liu, W.-h. Yu, H. Hu, Y.-m. Zheng, J.-h. Yan, Y.-h. Sun, J.-w. Liang, F.-h. Meng, T.-j. Zhang, Discovery and structural-activity relationship of N-benzyl-2-fluorobenzamides as EGFR\/HDAC3 dual-target inhibitors for the treatment of triple-negative breast cancer, Bioorg Med Chem Lett, 128 (2025) 130362.","DOI":"10.1016\/j.bmcl.2025.130362"},{"key":"10.1016\/j.bmc.2026.118707_bb0135","doi-asserted-by":"crossref","unstructured":"Y. Zhang, Y.-p. Wang, S. Guo, T.-t. Li, Q.-y. Wang, X. Zhang, Y.-m. Zheng, Y.-q. Wen, F.-h. Meng, T.-j. Zhang, Novel E-F ring derivatives of aconitine scaffold as potent Hsp90 inhibitors for the treatment of colorectal cancer, Eur J Med Chem, 296 (2025) 117895.","DOI":"10.1016\/j.ejmech.2025.117895"},{"key":"10.1016\/j.bmc.2026.118707_bb0140","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/nsmb.2673","article-title":"Structure of a pseudokinase-domain switch that controls oncogenic activation of jak kinases","volume":"20","author":"Toms","year":"2013","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.bmc.2026.118707_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118274","article-title":"Allosteric inhibition of JAK2 with lysine-reactive compounds that bind the pseudokinase domain","volume":"302","author":"Primi","year":"2026","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118707_bb0150","doi-asserted-by":"crossref","first-page":"7195","DOI":"10.1021\/acs.jmedchem.5b00301","article-title":"Discovery of VX-509 (Decernotinib): a potent and selective Janus kinase 3 inhibitor for the treatment of autoimmune diseases","volume":"58","author":"Farmer","year":"2015","journal-title":"J Med Chem"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096808962600163X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096808962600163X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T20:09:16Z","timestamp":1783109356000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096808962600163X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":30,"alternative-id":["S096808962600163X"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118707","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of potential covalent TYK2 inhibitors targeting Cys736 for the treatment of psoriasis","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118707","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118707"}}